These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6697677)

  • 21. The effect of caffeine on the absorption of 3H-dihydroergocryptine (DHEC) in the rat.
    Down WH; Chasseaud LF; Ballard SA
    Arzneimittelforschung; 1980; 30(11):1887-8. PubMed ID: 6779823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of rifampin administration on the disposition of fexofenadine.
    Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD
    Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic analysis of intravenously and orally administered quinidine in cows.
    McGuirk SM; Muir WW; Sams RA
    Am J Vet Res; 1981 Sep; 42(9):1482-7. PubMed ID: 7325456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dietary salt increases first-pass elimination of oral quinidine.
    Darbar D; Dell'Orto S; Mörike K; Wilkinson GR; Roden DM
    Clin Pharmacol Ther; 1997 Mar; 61(3):292-300. PubMed ID: 9084454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
    Pope LE; Khalil MH; Berg JE; Stiles M; Yakatan GJ; Sellers EM
    J Clin Pharmacol; 2004 Oct; 44(10):1132-42. PubMed ID: 15342614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative bioavailability characteristics of commercial quinidine polygalacturonate and sulfate tablets.
    Dahl JR; Ueda CT; Meyers DG; Wulf BG
    DICP; 1990; 24(7-8):685-8. PubMed ID: 2375136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
    Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
    Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired elimination of caffeine by oral contraceptive steroids.
    Patwardhan RV; Desmond PV; Johnson RF; Schenker S
    J Lab Clin Med; 1980 Apr; 95(4):603-8. PubMed ID: 7359014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition kinetics of quinidine.
    Ueda CT; Hirschfeld DS; Scheinman MM; Rowland M; Williamson BJ; Dzindzio BS
    Clin Pharmacol Ther; 1976 Jan; 19(1):30-6. PubMed ID: 1245091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers.
    Barone JA; Moskovitz BL; Guarnieri J; Hassell AE; Colaizzi JL; Bierman RH; Jessen L
    Pharmacotherapy; 1998; 18(2):295-301. PubMed ID: 9545149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition kinetics of two oral forms of quinidine.
    Mahon WA; Mayersohn M; Inaba T
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):566-75. PubMed ID: 1277713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absolute quinidine bioavailability.
    Ueda CT; Williamson BJ; Dzindzio BS
    Clin Pharmacol Ther; 1976 Sep; 20(3):260-5. PubMed ID: 954347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics of some antiarrhythmic drugs.
    Ochs HR; Greenblatt DJ; Bodem G
    Herz; 1979 Aug; 4(4):330-43. PubMed ID: 391683
    [No Abstract]   [Full Text] [Related]  

  • 37. Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies.
    Guentert TW; Holford NH; Coates PE; Upton RA; Riegelman S
    J Pharmacokinet Biopharm; 1979 Aug; 7(4):315-30. PubMed ID: 512840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug interactions of the components of Optalidon after oral administration.
    Lavene D; Longchampt J; Guillaume MF; Kiger JL
    Int J Clin Pharmacol Biopharm; 1976 Jun; 13(4):235-45. PubMed ID: 965130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disposition kinetics of oral quinidine when administered concurrently with propranolol.
    Kates RE; Blanford MF
    J Clin Pharmacol; 1979 Jul; 19(7):378-83. PubMed ID: 479382
    [No Abstract]   [Full Text] [Related]  

  • 40. [Estimation of residual rate and apparent half-life time of drugs using the method of acute mortality of animals].
    He MS; Zhan LF; Guo JY; Zhang YZ
    Zhongguo Yao Li Xue Bao; 1985 Sep; 6(3):213-6. PubMed ID: 2943131
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.